VIGL Vigil Neuroscience, Inc. revenue, earnings and financials
For the quarter ended June 30, 2025, Vigil Neuroscience, Inc. reported revenue of n/a, net income of −$26.7M and diluted EPS of −$0.56; for the fiscal year ended December 2024 revenue was n/a.
VIGL annual revenue and earnings
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$89.7M, net income −$84.3M (margin n/a), EPS −$2.07
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$88.9M, net income −$82.6M (margin n/a), EPS −$2.13
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$68.9M, net income −$68.3M (margin n/a), EPS −$2.16
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$42.4M, net income −$43.3M (margin n/a), EPS −$28.26
VIGL quarterly revenue and earnings
- Quarter ended Jun 30, 2025: revenue n/a, net income −$26.7M, EPS −$0.56
- Quarter ended Mar 31, 2025: revenue n/a, net income −$22.4M, EPS −$0.49
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$23.8M, EPS −$0.58
- Quarter ended Sep 30, 2024: revenue n/a, net income −$19.3M, EPS −$0.47
- Quarter ended Jun 30, 2024: revenue n/a, net income −$21.2M, EPS −$0.52
- Quarter ended Mar 31, 2024: revenue n/a, net income −$19.9M, EPS −$0.50
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$22.2M, EPS −$0.57
- Quarter ended Sep 30, 2023: revenue n/a, net income −$20.5M, EPS −$0.53
- Quarter ended Jun 30, 2023: revenue n/a, net income −$20.2M, EPS −$0.52
- Quarter ended Mar 31, 2023: revenue n/a, net income −$19.8M, EPS −$0.51
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$18.5M, EPS −$0.45
- Quarter ended Sep 30, 2022: revenue n/a, net income −$17.5M, EPS −$0.53
- Quarter ended Jun 30, 2022: revenue n/a, net income −$17.0M, EPS −$0.60
- Quarter ended Mar 31, 2022: revenue n/a, net income −$15.3M, EPS −$0.58
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$13.0M, EPS −$8.34
- Quarter ended Sep 30, 2021: revenue n/a, net income −$10.7M, EPS −$6.98
- Quarter ended Jun 30, 2021: revenue n/a, net income −$11.4M, EPS −$7.48
- Quarter ended Mar 31, 2021: revenue n/a, net income −$8.19M, EPS −$5.46
VIGL cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$51.2M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$70.4M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$65.1M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$39.3M, share buybacks n/a
VIGL balance sheet
- Jun 30, 2025: cash $41.2M, total assets $86.7M, total liabilities $45.4M, shareholders' equity $41.3M
- Mar 31, 2025: cash $51.6M, total assets $107M, total liabilities $42.0M, shareholders' equity $65.1M
- Dec 31, 2024: cash $39.0M, total assets $118M, total liabilities $46.1M, shareholders' equity $71.6M
- Sep 30, 2024: cash $44.9M, total assets $131M, total liabilities $42.7M, shareholders' equity $88.6M
- Jun 30, 2024: cash $37.3M, total assets $108M, total liabilities $23.2M, shareholders' equity $85.3M
- Mar 31, 2024: cash $51.8M, total assets $125M, total liabilities $21.3M, shareholders' equity $104M
- Dec 31, 2023: cash $52.0M, total assets $141M, total liabilities $24.6M, shareholders' equity $116M
- Sep 30, 2023: cash $56.8M, total assets $159M, total liabilities $23.3M, shareholders' equity $136M
Is VIGL profitable?
No. Vigil Neuroscience, Inc. lost $92.2M over the last four quarters.
What is VIGL's EPS?
Diluted earnings per share over the last four quarters were −$2.10; −$0.56 in the latest quarter.